Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

When and how to de-escalate therapy in inflammatory bowel diseases

The latest Alimentary Pharmacology & Therapeutics evaluates studies that de-escalate therapy in IBD.

News image

Therapeutic objectives are currently evolving in inflammatory bowel diseases (IBD) from control of symptoms towards improvement of long-term disease outcomes.

In patients achieving remission, safety concerns – infections or neoplasia – and economic issues are prompting de-escalation strategies.

Drs Pariente and Laharie from France provide an overview of studies on de-escalating therapy in IBD.

The team performed a structured search in Pubmed, the Cochrane Library and EMBASE was performed using defined key words, including full text articles and abstracts in English language.

The research team identified 11 studies, investigating cessation of immunosuppressants (IS) and/or anti-TNF treatments.

In patients receiving immunosuppressants alone, relapse rate at 12 months after cessation is 20% in Crohn's
Alimentary Pharmacology & Therapeutics

Patients exposed to a combination of IS and anti-TNF have an increased risk for infections, especially due to opportunistic agent, without any clear signal for associated cancers when compared to those receiving single therapy.

In patients receiving IS alone, relapse rate at 12 months following IS cessation is close to 20% and 30% in Crohn's disease (CD) and ulcerative colitis (UC) respectively.

The team found no study specifically evaluating anti-TNF treatment withdrawal in case of scheduled anti-TNF monotherapy in IBD.

In patients receiving combination therapy with IS and infliximab (IFX) for at least 6 months, relapse rate of IFX failure following IS cessation is near to 20% at 24 months, and seems to be similar in patients who maintained combination therapy.

The researchers noted that in case of anti-TNF therapy, cessation in CD patients in combo-therapy proportion of relapse is high, close to 40% and 50% over 1 year and 2 years respectively.

Regarding higher risk of adverse events, some special situations – young males, pregnancy and elderly – should be managed specifically and de-escalating treatment considered.

Dr Laharie and colleague conclude, "De-escalating treatment strategy should be mainly considered in patients with high risk of severe adverse events and low relapse risk (patients in deep remission) after drug withdrawal."

"For these reasons, cessation of anti-TNF treatment and/or immunosuppressants should be a case by case decision in highly selected patients."

Aliment Pharmacol Ther 2014: 40(4): 338–353
25 July 2014

Go to top of page Email this page Email this page to a colleague

 21 November 2014

Advanced search
 21 November 2014 
Hepatic involvement in IgG4-related disease
 21 November 2014 
Mortality of chemoembolization in hepatocellular carcinoma
 21 November 2014 
Skin cancer in ulcerative colitis patients
 20 November 2014 
Global measures in chronic idiopathic constipation
 20 November 2014 
Macrophage activation in alcoholic hepatitis
 20 November 2014 
Covert hepatic encephalopathy and survival
 19 November 2014 
Thiopurine withdrawal in IBD
 19 November 2014 
Esophageal narrowing in esophageal eosinophilia
 19 November 2014 
Second intestinal resection in Crohn's
 18 November 2014 
Colorectal neoplasia and vitamin D
 18 November 2014 
Food-associated changes in the intestinal mucosa in IBS
 18 November 2014 
Alternative medicine use by US adults
 17 November 2014 
Allergy-related diseases and abdominal pain in childhood
 17 November 2014 
Treatment of obesity in primary care settings
 17 November 2014 
Diagnosis of monogenic very early onset IBD
 14 November 2014 
Second intestinal resection in Crohn's
 14 November 2014 
HCC risk in active stage Hep B
 14 November 2014 
Thiopurine and clinical remission in IBD
 13 November 2014 
Antibiotics and risk of new-onset Crohn’s
 13 November 2014 
Chronic Hep C genotype 1 treatment after relapse
 13 November 2014 
Chemoembolization for hepatocellular carcinoma
 12 November 2014 
Risk of hepatocellular carcinoma
 12 November 2014 
Abdominal symptom severity in chronic idiopathic constipation
 12 November 2014 
Screening colonoscopy
 11 November 2014 
Hepatocellular carcinoma in Hep B with nucleotide analogue
 11 November 2014 
Familial colorectal cancer screening
 11 November 2014 
Fecal microbiota transplant for C. diff
 10 November 2014 
STaples IPAA for ulcerative colitis
 10 November 2014 
Blood stream infections in acute liver failure
 10 November 2014 
Ig4-related disease
 07 November 2014 
Host and viral factors in chronic Hep C
 07 November 2014 
Celiac diagnosis without biopsy
 07 November 2014 
Pricing practices of gastroenterologists
 06 November 2014 

Colorectal surgery postdischarge occurrences and readmissions

 06 November 2014 
Thromboprophylaxis in IBD
 06 November 2014 
Steatosis biomarkers in NAFLD
 05 November 2014 
Readmission risk factors for patients with IBD
 05 November 2014 
Hysterectomy and colonoscopy completion
 05 November 2014 
Adalimumab in Crohn's disease
 04 November 2014 
Gut barrier dysfunction and CNS disorders
 04 November 2014 
Hemospray for nonvariceal upper GI bleeding
 04 November 2014 
Sleep duration and ulcerative colitis
 03 November 2014 
Mucosal pathophysiology in HIV and IBD
 03 November 2014 
Managing bleeding gastroduodenal ulcers
 03 November 2014 
Identifying inflammation in ulcerative colitis
 31 October 2014 
Pregnancy complications in celiac disease
 31 October 2014 
Pediatric NAFLD
 31 October 2014 
C. difficile infection with metronidazole
 30 October 2014 
Cirrhosis in women
 30 October 2014 
Costs in newly diagnosed patients with chronic constipation
 30 October 2014 
Constipation and colorectal cancer
 29 October 2014 
Quality of life after infection with E. coli
 29 October 2014 
IBS in primary care
 29 October 2014 
Sensorimotor activity in functional dyspepsia
 28 October 2014 
Increased bile acid synthesis in IBS-diarrhea
 28 October 2014 
Successful radiofrequency ablation for Barrett’s
 28 October 2014 
Risk factor for smaller final height in Crohn's
 27 October 2014 
Celiac disease and type 1 diabetes
 27 October 2014 
Gluten awareness among chefs
 27 October 2014 

PPI-responsive esophageal eosinophilia

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2014 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us